RVMD | Revolution Medicines, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	56.01 - 57.97
52 Week Range	20.86 - 62.40
Beta	1.16
Implied Volatility	83.76%
IV Rank	63.13%
Day's Volume	818,875
Average Volume	1,190,914
Shares Outstanding	168,219,000
Market Cap	9,600,258,330
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-02-13

Valuation
Profitability
Growth
Health
P/E Ratio	-15.59
Forward P/E Ratio	N/A
EPS	-3.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	443
Country	USA
Website	RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD's peers: AADI, ADCT, AGIO, AKRO, ALEC, ALLK, ALXO, ARVN, BDTX, BHVN, CABA, CCCC, CDXS, CGEM, CLDX, CYTK, DNLI, DTIL, DYN, ENTA, EVAX, EWTX, EXAI, FDMT, FGEN, FOLD, GLTO, HRMY, IDYA, IGMS, IMAB, INSM, ITOS, KYMR, KZR, LYEL, MRSN, NAUT, NKTX, OMER, PASG, PBYI, PLRX, PRAX, PRLD, PSTX, PTGX, RARE, RCKT, RGNX, RLMD, RNA, ROIV, BPMC, SANA, GLUE, TCRR, BCEL, STOK, FIXX, NRIX, RYTM, SLDB, SNDX, SRRK, SVRA, SWTX, TNGX, TPST, TVTX, VALN, VCEL, VNDA, VRDN, XOMA, YMAB, ZNTL, ZYME, QNCX, THRD, PROK

*Chart delayed

Analyzing fundamentals for RVMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see RVMD Fundamentals page.

Watching at RVMD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RVMD Technicals page.